Triple-Drug chemo blitz aims to boost stomach cancer survival
NCT ID NCT03773367
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen (FOLFOX) improves outcomes for patients with resectable stomach or gastroesophageal junction cancer. 60 participants receive the three-drug combo before and after surgery. The goal is to see if this stronger treatment leads to better tumor shrinkage and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluorouracil, Oxaliplatin, and Irinotecan (a three-drug chemotherapy combination)
- What this could lead to
- If successful, this could lead to a more effective chemotherapy regimen for resectable stomach cancer, potentially improving survival and cure rates.
- What could go wrong
- This is a small, early-phase (phase 2) trial with only 60 participants. The added drug (irinotecan) may increase side effects without improving outcomes. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centrallasarettet i Växjö
Vaxjo, 352 34, Sweden
-
Karolinska University Hospital
Stockholm, 141 86, Sweden
-
Lund University Hospital
Lund, 221 85, Sweden
-
Oslo University Hospital, Ullevål Hospital
Oslo, 0450, Norway